GSK PLC

Case Overview
45 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 04/07/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: GSK PLC |
Court: | Court: Eastern District of Pennsylvania |
Case Number: | Case Number: 2:25cv00618 |
Class Period: | Class Period: 02/05/2020 - 08/14/2022 |
Ticker: | Ticker: GSK |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired GSK PLC (“GSK” or the “Company”) (NYSE:GSK) securities during the period from February 5, 2020, through August 14, 2022 (“the Class Period”). Investors have until April 7, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
GSK is a pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide. For many years, GSK’s most lucrative product was a popular treatment for heartburn and acid reflux: Zantac, generically known as ranitidine. Zantac was developed in 1976, by Glaxo, a predecessor company to GSK. From the time Zantac launched in the U.S., Glaxo and GSK were in possession of an internal Company report which showed that ranitidine could create a highly carcinogenic compound called N-nitrosodimethylamine (“NDMA”). Specifically, in 1982, Glaxo scientists Richard Tanner found that ranitidine interacted with nitrites, a common chemical found in many foods, to create 232,000 nanograms of NDMA. The U.S. Food and Drug Administration (“FDA”) would later determine that the recommended acceptable intake was 96 nanogram – less than 0.05% of what Dr. Tanner had found. Glaxo buried Dr. Tannar’s resulting report, and its successor company, GSK, kept that report buried.
In 2019, independent laboratory Valisure tested Zantac under similar conditions and found NDMA in “every batch of every medication’ that it tested. Valisure reported these results to the FDA and to the public. In September and October 2019, GSK suspended its distribution of Zantac and initiated a voluntary recall. In April 2020, the FDA requested that manufacturers cease selling Zantac and any generic alternatives.
On August 10, 2022, a Deutsche Bank report alerted the market that it seemed “very possible” that GSK and other Zantac distributors “will incur the risk of some degree of shared liability, with the only real questions being what the magnitude of liability may be.” Whereas GSK claimed repeatedly to investors that scientific research did not support a correlation between Zantac and cancer, meaning that the Company did not face significant liability, the Deutsche Bank report forecasted that the total liability could be between $5 billion and $10 billion. On this news, the price of GSK shares fell by $2.57 per share, from $38.30 per share on August 9, 2022, to close at $35.73 on August 10, 2022.
Then, on August 15, 2022, when GSK admitted that it could, in fact, provide guidance and that its liability exposure was between $1 billion and $10 billion. The eventual settlement of $2.2 billion fell squarely in that range. On this news, the price of GSK shares fell by $1.08 per share, from $36.03 per share on August 12, 2022, to close at $34.95 per share on August 15, 2022.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market and that it had concealed an internal study that implicated the Company’s liability to Zantac users.
GSK is a pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide. For many years, GSK’s most lucrative product was a popular treatment for heartburn and acid reflux: Zantac, generically known as ranitidine. Zantac was developed in 1976, by Glaxo, a predecessor company to GSK. From the time Zantac launched in the U.S., Glaxo and GSK were in possession of an internal Company report which showed that ranitidine could create a highly carcinogenic compound called N-nitrosodimethylamine (“NDMA”). Specifically, in 1982, Glaxo scientists Richard Tanner found that ranitidine interacted with nitrites, a common chemical found in many foods, to create 232,000 nanograms of NDMA. The U.S. Food and Drug Administration (“FDA”) would later determine that the recommended acceptable intake was 96 nanogram – less than 0.05% of what Dr. Tanner had found. Glaxo buried Dr. Tannar’s resulting report, and its successor company, GSK, kept that report buried.
In 2019, independent laboratory Valisure tested Zantac under similar conditions and found NDMA in “every batch of every medication’ that it tested. Valisure reported these results to the FDA and to the public. In September and October 2019, GSK suspended its distribution of Zantac and initiated a voluntary recall. In April 2020, the FDA requested that manufacturers cease selling Zantac and any generic alternatives.
On August 10, 2022, a Deutsche Bank report alerted the market that it seemed “very possible” that GSK and other Zantac distributors “will incur the risk of some degree of shared liability, with the only real questions being what the magnitude of liability may be.” Whereas GSK claimed repeatedly to investors that scientific research did not support a correlation between Zantac and cancer, meaning that the Company did not face significant liability, the Deutsche Bank report forecasted that the total liability could be between $5 billion and $10 billion. On this news, the price of GSK shares fell by $2.57 per share, from $38.30 per share on August 9, 2022, to close at $35.73 on August 10, 2022.
Then, on August 15, 2022, when GSK admitted that it could, in fact, provide guidance and that its liability exposure was between $1 billion and $10 billion. The eventual settlement of $2.2 billion fell squarely in that range. On this news, the price of GSK shares fell by $1.08 per share, from $36.03 per share on August 12, 2022, to close at $34.95 per share on August 15, 2022.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market and that it had concealed an internal study that implicated the Company’s liability to Zantac users.